Related Searches: Tea Vitamin Nutrients Ingredients paper cup packing

Food & Health Ingredients
Health & Nutrition
Processing & Packaging
Starch & Starch Derivatives
You are here: Home >news >Nestlé Invests $200 Million More in Peanut Drug

Nestlé Invests $200 Million More in Peanut Drug

2020-02-07 foodprocessing

Tag: Nestlé Peanut allergies

Share       

Nestlé has doubled down on its bet on a new therapy for peanut allergies.

Palforzia, from Aimmune Therapeutics Inc., treats peanut allergies by reducing the trauma suffered by allergic individuals upon exposure to peanuts. A powder made from peanuts, Palforzia is administered in escalating doses over an 11-month period. It does not cure peanut allergies, and sufferers must continue to avoid peanuts, but it mitigates the potentially fatal consequences of peanut exposure.

The FDA approved Palforzia on Jan. 31, and Aimmune announced on Feb. 5 that Nestlé had invested another $200 million in the drug. Nestlé had previously made investments totaling $273 million.

Nestlé’s involvement is seen as a way to increase revenue from its Health Science division and pivot away from food, wher sales have stagnated.

E-newsletter

Subscribe to our e-newsletter for the latest food ingredients news and trends.

Tags

SJGLE B2B Website : 中文版 | ChineseCustomer Service: 86-400 610 1188-3 ( Mon-Fri 9: 00-18: 00 BJT)

About Us|Contact Us|Privacy Policy|Intellectual Property Statement

Copyright 2006-2023 Shanghai Sinoexpo Informa Markets International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-121  沪公网安备31010402001403号

Inquiry Basket

Inquiry Basket

Buyer service

Buyer service

Supplier service

Supplier service

Top

Top